Vaccine 2014-06-17

A protective chimeric antibody to tick-borne encephalitis virus.

Ivan K Baykov, Andrey L Matveev, Oleg V Stronin, Alexander B Ryzhikov, Leonid E Matveev, Marat F Kasakin, Vladimir A Richter, Nina V Tikunova

Index: Vaccine 32(29) , 3589-94, (2014)

Full Text: HTML

Abstract

The efficiency of several mouse monoclonal antibodies (mAbs) specific to the tick-borne encephalitis virus (TBEV) glycoprotein E in post-exposure prophylaxis was assessed, and mAb14D5 was shown to be the most active of all those studied. It was proven that the hybridoma cell line 14D5 produced one immunoglobulin H chain and two L chains. They were used to construct chimeric antibodies ch14D5a and ch14D5b, the affinity constants of which were 2.6 × 10(10)M(-1) and 1.0 × 10(7)M(-1), respectively, according to the SPR-based ProteOn biosensor assay. The neutralization index (IC50) of ch14D5a was 0.04 μg/ml in the focus reduction neutralization test. In in vivo experiments, ch14D5a at a dose of 10 μg/mouse resulted in a 100% survival of the mice infected with 240 LD50 of TBEV. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV.Copyright © 2014 Elsevier Ltd. All rights reserved.